RUNNING HEAD: Prostate-Specific Antigen 1 Prostate-Specific Antigen Joanna Cunningham Walden University NURS 6512, Advanced Health Assessment September 15, 2019
RUNNING HEAD: Prostate-Specific Antigen 2 Prostate-Specific Antigen Prostate cancer is cancer that occurs in the prostate, which consists of a gland in men that produces the seminal fluid that nourishes and transports sperm (Mayo Clinic, 2018). The American Cancer Society's (2019), estimates for prostate cancer in the United States for 2019 are about 174,650 new cases of prostate cancer and about 31,620 deaths from prostate cancer. The American Cancer Society (2019) recommends screening at "Age 50 for men who are at average risk of prostate cancer and are expected to live at least ten more years. Age 45 for men at high risk of developing prostate cancer. It is also known that men with first-degree relatives diagnosed with prostate cancer are at an increased risk of developing the disease and should be screened at an early age. Preventative services are essential to diagnose at an early stage. The purpose of this paper is to discuss the use of the prostate-specific antigen test, the validity and reliability of test, and explore issues such as sensitivity, reliability, and predictive values. Prostate-Specific Antigen Test Used Prostate cancer screening can often be done early by testing for prostate-specific antigen serum levels. Although, prostate cancer is considered slow-growing cancer, therefore, the effects of screening may become more evident within several years (American Cancer Society, 2018). Early testing is recommended to assist with early detection and treatment with a favorable outcome. The prostate-specific antigen (PSA) is a protein that is produced by noncancerous and cancerous tissues within the male prostate gland. The diagnostic test requires a blood sample
You've reached the end of your free preview.
Want to read all 6 pages?
- Summer '15